Author: ["Gerd Fätkenheuer","Anton L Pozniak","Margaret A Johnson","Andreas Plettenberg","Schlomo Staszewski","Andy I M Hoepelman","Michael S Saag","Frank D Goebel","Jürgen K Rockstroh","Bruce J Dezube","Tim M Jenkins","Christine Medhurst","John F Sullivan","Caroline Ridgway","Samantha Abel","Ian T James","Mike Youle","Elna van der Ryst"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10–15 d, with a mean reduction of ≥1.6 log10 copies/ml at all twice daily doses ≥100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.Cite this article
Fätkenheuer, G., Pozniak, A., Johnson, M. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11, 1170–1172 (2005). https://doi.org/10.1038/nm1319 